Cycloalkanopyridine derivative

Details Cycloalkanopyridine derivative Cycloalkanopyridine derivative

2005-03-04

2010-12-21

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S126000, C546S153000, C514S278000, C514S304000, C514S312000

Reexamination Certificate

active

07855294

ABSTRACT:
Provided are cycloalkanopyridine derivatives of formula [I]:[wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

REFERENCES:
patent: 4016281 (1977-04-01), Jonas et al.
patent: 4130646 (1978-12-01), Vogt et al.
patent: 6166209 (2000-12-01), Adam et al.
patent: 6869960 (2005-03-01), Ito et al.
patent: 7115633 (2006-10-01), Barlocco et al.
patent: 7125877 (2006-10-01), Kobayashi et al.
patent: 7223867 (2007-05-01), Palombi et al.
Churakov et. al. “Progress in 1,2,3,4-Tetrazine” Chemistry Chemical Reviews 2004, 104, 2601-2616.
Martin, Yvonne C. et. al. “Do Structurally Similar Molecules Have Similar Biological Activity?” Journal of Medicinal Chemistry 2002, 45, 4350-4358.
Sugimoto et. al. “Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists” Bioorganic & Medicinal Chemistry Letters 16 (2006) 3569-3573.
Chen et. al. “Design and Parallel Synthesis of Piperidine Libraries Targeting the Nociceptin (N/OFQ) Receptor.” Bioorganic & Medicinal Chemistry Letters 2003, 13, 3247-3252.
In the Pipeline, online, accessed Jun. 16, 2008, “http://pipeline.corante.com/archives/2006/01/24/the—examiner—finally—snaps.php”.
Bigan et al., “Recent Advances Towards the Discovery of ORL-1 Receptor Agonists and Antagonists”, Expert Opin. Ther. Patents, vol. 15, pp. 357-388, 2005.
Chiou et al., “Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications”, Current Drug Targets, vol. 8, pp. 117-135, 2007.
Niiyama et al., “6-Carboxy-5,7-Diarylcyclopentenol[1,2-b] Pyridine Derivatives: A Novel Class of Endothelin Receptor Antagonists”, Biorg. Med. Chem., vol. 10, pp. 2461-2470, 2002.
Pita et al., “A Simple, Efficient Method for Regioselective Synthesis of 7-Aminomehtyl-7,8-Dihydro-6H-Quinolin-5-ones, New Potential CNS Agents”, Tetrahedron Letters, vol. 41, pp. 9829-9833, 2000.
Ronzoni et al., “Lead Generation and Lead Optimisation Approaches in the Discovery of Selective, Non-Peptide ORL-1 Receptor Agonists and Antagonists”, Expert. Opin. Ther. Patents, vol. 11, pp. 525-546, 2001.
Zaratin et al., “Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (−) Cis-1-Methyl-7[[4-2,6-Dicholorphenyl) Piperidin-1-yl]Methyl]-6,7,8,9-Tetrahydro-5H-Benzocyclophepten-5-ol (SB-612111)”, J. of Pharmacology and Experimental Therapeutics, vol. 308, pp. 454-461, 2004.
Yoshizumi et al., “A Novel Class of Cycloalkano[b] Pyridines as Potent and Orally Active Opioid Receptor-Like 1 Antagonists with Minimal Binding Affinity to the hERG K+ Channel”, J. Med. Chem, vol. 51, pp. 4021-4029, 2008.
Zaveri et al., “Peptide and NonPeptide Ligands for the Nociceptin/Orphanin FQ Receptor ORL1: Research Tools and Potential Therapeutic Agents”, Life Sciences, vol. 73, pp. 663-678, 2003.

Affiliated with

Also associated with

Rating

Cycloalkanopyridine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cycloalkanopyridine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkanopyridine derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4228841